Natural killer cells target HCV core proteins during the innate immune response in HCV transgenic mice

Journal of Medical Virology

Volumn 82, Issue 9, 2010, Pages 1545-1553

  Satoh, Kenichi ^a,b   Takahashi, Hiroki ^b   Matsuda, Chiho ^a   Tanaka, Toshiyuki ^c   Miyasaka, Masayuki ^d   Zeniya, Mikio ^b   Kohara, Michinori ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Core protein; Cre loxP switching Tg; HCV; Innate immunity; Natural killer cell

Indexed keywords

ALANINE AMINOTRANSFERASE; CORE PROTEIN; GAMMA INTERFERON;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA RECOMBINATION; GENOMICS; HEPATITIS C; HEPATITIS C VIRUS; INNATE IMMUNITY; LIVER CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REGULATORY MECHANISM;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; IMMUNITY, INNATE; KILLER CELLS, NATURAL; LIVER; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; VIRAL CORE PROTEINS; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS; MUS; MUS MUSCULUS;

EID: 77956572699     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21859     Document Type: Article

References (37)

1. Ahmad A, Alvarez F. 2004. Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis. J Leukoc Biol 76:743-759.
2. Bigger CB, Brasky KM, Lanford RE. 2001. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 75:7059-7066.
3. Blight KJ, Kolykhalov AA, Rice CM. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974.
4. Carroll JM, Crompton T, Seery JP, Watt FM. 1997. Transgenic mice expressing IFN-gamma in the epidermis have eczema, hair hypopigmentation, and hair loss. J Invest Dermatol 108:412-422.
5. Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U, Mosca M, Filliponi F, Brunetto RM, Bonino F, Abrignani S, Valiante NM. 2002. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 195:35-41.
6. Disson O, Haouzi D, Desagher S, Loesch K, Hahne M, Kremer EJ, Jacquet C, Lemon SM, Hibner U, Lerat H. Impaired clearance of virus-infected hepatocytes in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2004. 126:859-872.
7. Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, Szabo G. 2004. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 127:1513-1524.
8. Duncan GS, Mittrucker HW, Kagi D, Matsuyama T, Mak TW. 1996. The transcription factor interferon regulatory factor-1 is essential for natural killer cell function in vivo. J Exp Med 184:2043-2048.
9. Ebihara T, Shingai M, Matsumoto M, Wakita T, Seya T. 2008. Hepatitis C virus-infected hepatocytes extrinsically modulate dendritic cell maturation to activate T cells and natural killer cells. Hepatology 48:48-58.
10. French AR, Yokoyama WM. 2003. Natural killer cells and viral infections. Curr Opin Immunol 15:45-51.
11. Frese M, Schwarzle V, Barth K, Krieger N, Lohmann V, Mihm S, Haller O, Bartenschlager R. 2002. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35:694-703.
12. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, Schrirren CA, Waechtler M, Backmund M, Pape GR. 2003. Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125:80-88.
13. Golden-Mason L, Madrigal-Estebas L, McGrath E, Conroy MJ, Ryan EJ, Hegarty JE, O'Farrelly C, Doherty DG. 2008. Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut 57:1121-1128.
14. Golden-Mason L, Rosen HR. 2006. Natural killer cells: Primary target for hepatitis C virus immune evasion strategies? Liver Transpl 12:363-372.
15. Irshad M, Khushboo I, Singh S, Singh S. 2008. Hepatitis C virus (HCV): A review of immunological aspects. Int Rev Immunol 27:497-517.
16. Kashiwakuma T, Hasegawa A, Kajita T, Takata A, Mori H, Ohta Y, Tanaka E, Kiyosawa K, Tanaka T, Tanaka S, Hattori N, Kohara M. 1996. Detection of hepatitis C virus specific core protein in serum of patients by a sensitive fluorescence enzyme immunoassay (FEIA). J Immunol Methods 190:79-89.
17. Knapp S, Warshow U, Hegazy D, Brackbury L, Guha IN, Fowell A, Little AM, Alexander GJ, Rosenberg WM, Cramp ME, Khakoo SI. 2009. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology 51:1-8.
18. Lanford RE, Guerra B, Lee H, Averett DR, Pfeiffer B, Chavez D, Notvall L, Bigger C. 2003. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol 77:1092-1104.
19. Liu F, Song Y, Liu D. 1999. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6:1258-1266.
20. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
21. Machida K, Tsukiyama-Kohara K, Seike E, Tone S, Shibasaki F, Shimizu M, Takahashi H, Funata N, Taya C, Yonekawa H, Kohara M. 2001. Inhibition of cytochrome c release in Fas-mediated signaling pathway in transgenic mice induced to express hepatitis C viral proteins. J Biol Chem 276:12140-12146.
22. Major ME, Mihalik K, Puig M, Rehermann B, Nascimbeni M, Rice CM, Feinstone SM. 2002. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 76:6586-6595.
23. Matsuyama T, Kimura T, Kitagawa M, Pfeffer K, Kawakami T, Watanabe N, Kundig TM, Amakawa R, Kishihara K, Wakeham A. 1993. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 75:83-97.
24. Minakuchi Y, Takeshita F, Kosaka N, Sasaki H, Yamamoto Y, Kouno M, Honma K, Nagahara S, Hanai K, Sano A, Kato T, Terada M, Ochiya T. 2004. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 32:e109.
25. Ochiya T, Nagahara S, Sano A, Itoh H, Terada M. 2001. Biomaterials for gene delivery: Atelocollagen-mediated controlled release of molecular medicines. Curr Gene Ther 1:31-52.
26. Ohteki T, Yoshida H, Matsuyama T, Duncan GS, Mak TW, Ohashi PS. 1998. The transcription factor interferon regulatory factor 1 (IRF-1) is important during the maturation of natural killer 1.1+ T cell receptor-alpha/beta+ (NK1+ T) cells, natural killer cells, and intestinal intraepithelial T cells. J Exp Med 187:967-972.
27. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, Jens B, Purcell RH, Schultz PG, Chisari FV. 2002. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 99:15669-15674.
28. Takaku S, Nakagawa Y, Shimizu M, Norose Y, Maruyama I, Wakita T, Takano T, Kohara M, Takahashi H. 2003. Induction of hepatic injury by hepatitis C virus-specific CD8+ murine cytotoxic T lymphocytes in transgenic mice expressing the viral structural genes. Biochem Biophys Res Commun 301:330-337.
29. Tanaka T, Kitamura F, Nagasaka Y, Kuida K, Suwa H, Miyasaka M. 1993. Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice. J Exp Med 178:1103-1107.
30. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. 2001. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194:1395-1406.
31. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, Govindarajan S, Purcell RH, Chisari FV. 2002. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 99:15661-15668.
32. Tseng CT, Klimpel GR. 2002. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 195:43-49.
33. Tsukiyama-Kohara K, Tone S, Maruyama I, Inoue K, Katsume A, Nuriya H, Ohmori H, Ohkawa J, Taira K, Hoshikawa Y, Shibasaki F, Reth M, Minatogawa Y, Kohara M. 2004. Activation of the CKI-CDK-Rb-E2F pathway in full genome hepatitis C virus-expressing cells. J Biol Chem 279:14531-14541.
34. Vidal-Castineira JR, Lopez ZA, Diaz PR, Alonso AR, Martinez BJ, Perez R, Fernandez SJ, Melon S, Prieto J, Rodrigo L, López LC. 2010. Effect of killer immunogloblin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol 84: 475-481.
35. Vilasco M, Larrea E, Vitour D, Dabo S, Breiman A, Reqnault B, Riezu JI, Eid P, Prieto J, Meurs EF. 2006. The protein kinase IKKepsilon can inhibit HCV expression independently of IFN and its own expression is downregulated in HCV-infected livers. Hepatology 44:1635-1647.
36. Wakita T, Taya C, Katsume A, Kato J, Yonekawa H, Kanegae Y, Saito I, Hayashi Y, Koike M, Kohara M. 1998. Efficient conditional transgene expression in hepatitis C virus cDNA transgenic mice mediated by the Cre/loxP system. J Biol Chem 273:9001-9006.
37. Yoon JC, Shiina M, Ahlenstiel G, Rehermann B. 2008. Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology 49:12-21.